Stifel’s investment banking professionals are committed to serving the needs of European companies through specialized expertise and strong relationships within our core industries. It is our fundamental belief that clients value genuine advice and long-term relationships, and we seek to provide these across a full range of industry coverage groups.
We are pleased to welcome ACXIT Capital Partners to Stifel. ACXIT is a leading independent corporate finance and financial advisory firm serving European middle-market clients and entrepreneurs. The ACXIT team extends our platform further into the German, Austrian and Swiss markets.
The Canton of Basel-Stadt contributes to the further development of convention-related tourism. Conventions are specifically acquired, developed and held, thus accessing a potential not yet exploited with benefits beyond tourism.
The objective of convention promotion is to increase the direct and indirect added value generated by conventions. Additionally, a further strengthening of Basel as the most innovative economic location and center of knowledge in Switzerland is targeted. By promoting conventions, we want to contribute to Basel remaining one of the most important trade fair and convention cities in Europe.
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 8,000 colleagues across five continents.
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives by promoting innovation. We connect the right people and the right topics across European borders, so that innovation can happen at the intersection of research, education and business.
With global presences in New York, Boston, San Francisco / Silicon Valley, Chicago, Charlotte, London, Zurich, Paris, Milan, and Tel-Aviv, LifeSci Partners leverages its relationships and knowledge in multiple territories around the world to provide high value services in investor relations & corporate access, communications, BD&L & strategic consulting, search, expert network access, venture, equity research & banking.
A global investment banking boutique serving companies in the life sciences industry. Since our inception in 2007, we have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks. We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, pharmaceutical asset sale, capital markets, and licensing transactions. Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence. Over half the transactions on which we advise are cross-border. Torreya has offices in London, Mumbai, and New York, and affiliate offices on six continents.
We are Merck KGaA, Darmstadt, Germany, a vibrant science and technology company.
Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create.
The passion of our curious minds makes a positive difference to millions of people’s lives every day.
In Healthcare, we discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. Our Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information.
Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live.
We put health at the heart of our work. BiomedVC is a leading Swiss early-stage VC at the center of European biotech. We build companies around the most intriguing innovation, targeting Seed and Series A investments in companies developing therapeutics for high unmet medical need indications. We strive to enable founders and their ideas. We focus on scientific excellence, building strong companies to create medical and commercial value and bring new medicines to market that improve patient’s lives.
Latham & Watkins LLP is one of the largest law firms in the world with more than 3,000 lawyers located in major financial, business and regulatory centers around the globe. Our award-winning Healthcare & Life Sciences Industry guides clients through their most significant and cutting-edge legal challenges through a combination of in-depth industry knowledge, legal acumen, and strategic business advice. We understand the unique economic, market, regulatory and political climates in which healthcare and life sciences companies operate. www.lw.com/
Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Novo Ventures is a global team of investment professionals employed by Novo affiliates that supports Novo Holdings’ investments in private, public and structured product opportunities in the life sciences industry. Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding and investment company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Foundation’s assets. Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts from innovators to large pharma makes us uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures’ services include: • M&A (divestments, mergers, acquisitions, and strategic transactions) • Licensing (in and out licensing) • Fundraising • Strategy (commercialisation, deal strategy, due diligence, market entry) • Valuation and Positioning (licensing, M&A, fundraising, and expert testimonies)
PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Asia-Pacific. PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).
Quan capital is a life sciences venture capital firm with strong China expertise and global capabilities. We discover, incubate, and grow next-generation life science companies in early and growth stage, worldwide. Our portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs.
Quan has offices in Shanghai, Menlo Park and Boston. Our investment professionals combine their strong expertise in both science and business with their diverse experiences in global drug development and healthcare investments, and they leverage their broad network worldwide to help maximize the company’s value across geographies and development stages. www.quancapital.com